Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.55% | -333.46% | 86.18% | -160.26% | 373.60% |
| Total Depreciation and Amortization | -3.69% | -4.08% | 1.59% | 1.00% | -1.69% |
| Total Amortization of Deferred Charges | -4.85% | 5.09% | 17.83% | 6.76% | -3.93% |
| Total Other Non-Cash Items | -65.90% | 43.55% | -57.59% | 174.59% | -2,239.03% |
| Change in Net Operating Assets | -144.54% | 62.93% | 193.57% | -192.32% | 151.55% |
| Cash from Operations | -189.37% | -22.06% | 174.37% | -28.92% | 132.26% |
| Capital Expenditure | 69.94% | -19.46% | -46.08% | -288.57% | 74.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 113.47% | 17.43% | 15.53% | -1,380.95% | 62.81% |
| Cash from Investing | 112.67% | 16.95% | 15.07% | -1,350.57% | 63.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.67% | 40.00% | -150.00% | 20.00% | 0.00% |
| Issuance of Common Stock | -92.52% | 163.97% | 123.98% | -37.58% | 134.51% |
| Repurchase of Common Stock | -359.48% | -1,448.00% | -- | 100.00% | -1,096.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.79% | -200.97% | 59,433.33% | -39.02% | 95.68% |
| Cash from Financing | -123.28% | -62.98% | 480.34% | -22.09% | 129.20% |
| Foreign Exchange rate Adjustments | 168.35% | -510.61% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -379.90% | -80.90% | 242.33% | -217.74% | 776.58% |